

Cover Story
FreeGuest Editorial
When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.This is a formidable challenge. Cancer trials were, and remain, notoriously time-consuming to launch, expensive to run, and difficult to enroll patients to. A deeper understanding of cancer biology and the genomics revolution in medicine have changed how we approach clinical research.When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.
In Brief


Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- George Sigounas named the first-ever chief science advisor at NCI
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Makary: Level of evidence is an artificial and dogmatic construct
- Reimagining cancer care for a new generation of patients